Samer Al Hadidi, Associate Professor at UT Southwestern Medical Center, shared a post on X:
“ENDURANCE – most important findings:
- No OS difference (2/3 of pts alive at 7 yrs follow up in both arms) and no meaningful PFS benefit (only 6% difference).
- Substantially more toxicity with continuous therapy.
- Even in the arm assigned to continue indefinitely, only 14% of patients were still on treatment at the data-cutoff (nearly 12 years in), most stopped anyway, largely due to cumulative low-grade toxicity (fatigue, neuropathy, diarrhea) or disease progression.
Time to move from ‘indefinite’ maintenance in standard risk disease and with better available therapies hope we can even do shorter than 2 years I’d maintenance therapy.”
Title: Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
Authors: Shaji Kumar, Susanna Jacobus, Adam Cohen, Matthias Weiss, Natalie Callander, Avina Singh, Terri Parker, Michael Green, Raymond Thertulien, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Elie Dib, Daniel Almquist, Jeffrey Zonder, Edward Faber, Zihan Wei, Kenneth Anderson, Sagar Lonial, Paul Richardson, Robert Orlowski, Lynne Wagner, S. Vincent Rajkumar
You can also read:
